Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report.
10.3779/j.issn.1009-3419.2021.102.39
- Author:
Junjie GU
1
;
Fan BAI
2
;
Lan SONG
3
;
Yingyi WANG
4
Author Information
1. Department of Internal Medicine,
Peking Union Medical College Hospital, Beijing 100730, China.
2. Department of Pharmacy,Peking Union Medical College Hospital, Beijing 100730, China.
3. Department of Radiology,
Peking Union Medical College Hospital, Beijing 100730, China.
4. Department of Oncology,
Peking Union Medical College Hospital, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor;
Interstitial lung disease;
Lung neoplasms;
Osimertinib
- MeSH:
Acrylamides/therapeutic use*;
Aniline Compounds/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/genetics*;
ErbB Receptors/genetics*;
Humans;
Lung Diseases, Interstitial/genetics*;
Lung Neoplasms/genetics*;
Male;
Middle Aged;
Prednisone;
Protein Kinase Inhibitors/adverse effects*
- From:
Chinese Journal of Lung Cancer
2021;24(11):804-807
- CountryChina
- Language:Chinese
-
Abstract:
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with osimertinib 80 mg/d for first-line targeted therapy. On day 60 after initiating treatment of osimertinib, the patient developed ILD. Osimertinib was discontinued immediately and oral prednisone 60 mg/d was initiated, ILD improved within 13 d. After balancing the risk and benefit, osimertinib was restarted concurrently with prednisone. The patient showed neither disease progression nor a recurrence of ILD for more than 16 months. Based on our case and literature review, retreatment with osimertinib under steroid coverage could be considered as an effective treatment option after careful risk-benefit assessment for patients with EGFR-mutant NSCLC.
.
